Cite

HARVARD Citation

    Pratz, K. et al. (2022). Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of clinical oncology. 40 (8), pp. 855-865. [Online]. 
  
Back to record